Renal and blood pressure effects of dapagliflozin in recently hospitalized patients with heart failure with mildly reduced or preserved ejection fraction: Insights from the DELIVER trial

Aims

Patients recently hospitalized for heart failure (HF) often have unstable haemodynamics and experience worsening renal failure, and are at elevated risk for recurrent HF events. In DELIVER, dapagliflozin reduced HF events or cardiovascular death including among patients who were hospitalized or recently hospitalized.

Methods and results

We examined the effects of dapagliflozin versus placebo on estimated glomerular filtration rate (eGFR) slope (acute and chronic), 1-month change in systolic blood pressure, and the occurrence of serious hypovolaemic or renal adverse events in patients with and without HF hospitalization within 30 days of randomization. The 654 (90 randomized during hospitalization, 147 1–7 days post-discharge and 417 8–30 days post-discharge) recently hospitalized patients had lower baseline eGFR compared with those without recent HF hospitalization (median [interquartile range] 55 [43, 71] vs. 60 [47, 75] ml/min/1.73 m²). Dapagliflozin consistently reduced the risk of all-cause (p_interaction = 0.20), cardiac-related (p_interaction = 0.75), and HF-specific (p_interaction = 0.90) hospitalizations, irrespective of recent HF hospitalization. In those recently hospitalized, acute placebo-corrected eGFR reductions with dapagliflozin were modest and similar to patients without recent hospitalization (−2.0 [−4.1, +0.1] vs. −3.4 [−3.9, −2.9] ml/min/1.73 m², p_interaction = 0.12). Dapagliflozin's effect to slow chronic eGFR decline was similar regardless of recent hospitalization (p_interaction = 0.57). Dapagliflozin had a minimal effect on 1-month systolic blood pressure and to a similar degree in patients with and without recent hospitalization (−1.3 vs.−1.8 mmHg, p_interaction = 0.64). There was no treatment-related excess in renal or hypovolaemic serious adverse events, irrespective of recent HF hospitalization.

Conclusion

In patients recently hospitalized with HF, initiation of dapagliflozin had minimal effects on blood pressure and did not increase renal or hypovolaemic serious adverse events, yet afforded long-term cardiovascular and kidney protective effects. These data suggest that the benefit to risk ratio favours initiation of dapagliflozin among stabilized patients hospitalized or recently hospitalized for HF. Clinical Trial Registration: ClinicalTrials.gov NCT03619213.     

Renewable energy management of an hybrid water pumping system (photovoltaic/wind/battery) based on Takagi–Sugeno fuzzy model

This research work presents an optimal energy management for a hybrid water pumping system driven by a photovoltaic generator (PVG) and a wind turbine. These two renewable energies are used as power generation sources, whereas a battery is added as an energy-storing system, for the purpose of controlling the power flow and providing a constant load supply. The proposed management system, serve to guarantee the pumping system autonomy in a rural region where's no access to the electrical network. As a result, a maximum power point tracking (MPPT) controller is created based on the fuzzy Takagi–Sugeno (TS) model, ensuring maximum power transfer to the moto-pump in spite of wind speed and insolation changes. The synthesis of MPPT control law involves TS fuzzy reference models which generate the desired trajectories to track. A supervisor has been developed for energy management and its major purpose is to effectively use the battery to satisfy the power load requirements, and that is by maintaining the state of charge (SOC) to extend the battery's life. Finally, simulation results have been done based on Matlab/Simulink with the aim of validating the efficiency of the proposed energy management supervisor.